Safety of fexofenadine and other second-generation oral antihistamines before and after the removal of the prescription requirement in Italy and other European countries: A real-world evidence study and systematic review-Reference-Cited by-同舟云学术

Safety of fexofenadine and other second-generation oral antihistamines before and after the removal of the prescription requirement in Italy and other European countries: A real-world evidence study and systematic review

Published:2022-07 Issue:7 Volume:15 Page:100658
ISSN:1939-4551
Container-title:World Allergy Organization Journal
language:en
Short-container-title:World Allergy Organization Journal

Author:

Carnovale Carla,Battini Vera,Gringeri Michele,Volonté Marina^ORCID,Uboldi Maria Chiara,Chiarenza Andrea,Passalacqua Giovanni

Funder

Sanofi

Publisher

Elsevier BV

Subject

Immunology and Allergy,Immunology,Pulmonary and Respiratory Medicine

Reference53 articles.

1. The prescription to over-the-counter switches and double registration of medicines - the perspective of pharmacists from the Greater Poland;Zaprutko;Clin Exp Allergy,2019

2. Rx-to-OTC Switch;Association CHP,2022

3. To switch or not to switch—first Germany-wide study from the perspective of pharmacists in the European environment;Stippler;J Public Health,2021

4. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review;Devillier;Clin Pharmacokinet,2008

5. A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis;Bilkhu;Contact Lens Anterior Eye: J Br Contact Lens Assoc,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High‐risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database;Clinical and Translational Allergy;2024-09

2. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM;Clinical Therapeutics;2024-03

3. Update meta-analysis on the efficacy and safety issues of fexofenadine;World Allergy Organization Journal;2023-07